Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal oxybutynin for overactive bladder.

G Willy Davila1, Jonathan S Starkman, Roger R Dmochowski

  • 1Department of Gynecology, Section of Urogynecology and Reconstructive Pelvic Surgery, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA. davilag@ccf.org

The Urologic Clinics of North America
|October 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urobiome Analysis in Interstitial Cystitis/Bladder Pain Syndrome Reveals Nuanced Differences Associated with Localized Pain.

International urogynecology journal·2026
Same author

Treatment of refractory idiopathic overactive bladder with incobotulinumtoxinA and vibe delivery system (XAVIER): pilot study.

Minerva urology and nephrology·2026
Same author

Cost-utility of implantable tibial neuromodulation (Revi) versus conservative therapy for urgency urinary incontinence in adults: a US payer perspective.

Journal of medical economics·2026
Same author

Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study.

The Journal of urology·2026
Same author

Impact of Revi® Implantable Tibial Neuromodulation on Quality of Life in Patients with Urgency Urinary Incontinence.

International urogynecology journal·2026
Same author

Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder.

Journal of comparative effectiveness research·2025
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Transcutaneous oxybutynin offers an effective treatment for overactive bladder, maintaining symptom control while significantly reducing dry mouth and other side effects common with oral anticholinergic drugs.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Overactive bladder (OAB) is frequently managed with oral anticholinergic medications like oxybutynin chloride.
  • While effective for urgency, frequency, and incontinence, oral anticholinergics often cause side effects, notably dry mouth, leading to treatment discontinuation.
  • N-desethyloxybutynin, a metabolite of oxybutynin, is associated with these anticholinergic adverse events.

Purpose of the Study:

  • To evaluate a transcutaneous formulation of oxybutynin for OAB treatment.
  • To assess if transcutaneous delivery maintains efficacy while mitigating common anticholinergic side effects.

Main Methods:

  • Administration of oxybutynin via a transcutaneous delivery system.
  • Comparison of efficacy and side effect profiles with oral oxybutynin therapy.

Related Experiment Videos

Main Results:

  • Transcutaneous oxybutynin demonstrated efficacy comparable to oral formulations in managing OAB symptoms.
  • Significantly reduced incidence of dry mouth and other anticholinergic side effects was observed with transcutaneous delivery.
  • Transcutaneous delivery bypasses hepatic and gastrointestinal metabolism, reducing the formation of N-desethyloxybutynin.

Conclusions:

  • Transcutaneous oxybutynin provides a well-tolerated and effective therapeutic option for patients with overactive bladder and urge urinary incontinence.
  • This novel formulation improves treatment adherence by minimizing bothersome side effects associated with oral anticholinergic therapy.